News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
AMI to become part of Enpro’s Sealing Technologies Segment
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
Subscribe To Our Newsletter & Stay Updated
